ALNY

Q: What is the price of Alnylam Pharmaceuticals (ALNY) today?

The current price of Alnylam Pharmaceuticals (ALNY) is $ 295.63, representing a -2.93% gain over the past year. The stock began the year trading around $ 397.65 and is currently priced at $ 295.63. You can follow the real-time price chart, review historical performance, and track broader market trends directly on the platform.

Q: When does Alnylam Pharmaceuticals (ALNY) pay dividends?

Alnylam Pharmaceuticals (ALNY) did not pay dividends over the past year.

Alnylam Pharmaceuticals Inc.

Price

$ 295.63

return (12m)

-2.93%

p/e

72.32

p/bv

38.82

DIVIDEND YIELD

0.00%

ALNY price

Alnylam Pharmaceuticals

If you had invested

exposure

years ago

7 days

30 days

6 months

YTD

1 year

5 years

10 years

15 years

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

Return on Investment ALNY

1 month

3 months

1 year

2 years

5 years

10 years

return

1 month

-0.16%

3 months

-7.22%

1 year

-2.93%

2 years

96.50%

5 years

100.71%

10 years

307.20%

Fundamentals ALNY

review the fundamentals of Alnylam Pharmaceuticals shares

P/E

72.32

Sector: -3.99 Industry: -3.99

P/S (PSR)

9.74

Sector: -4.17 Industry: -4.17

P/BV

38.82

Sector: 2.00 Industry: 2.00

DIVIDEND YIELD (DY)

0.00%

Sector: - Industry: -

ROA

11.25%

Sector: -65.15% Industry: -65.15%

ROE

53.68%

Sector: -65.39% Industry: -65.39%

ROIC

Sector: -2,913.92% Industry: -2,913.92%

NET MARGIN

13.46%

Sector: -40.35% Industry: -40.35%

GROSS MARGIN

80.89%

Sector: 36.51% Industry: 36.51%

OPERATING MARGIN

17.54%

Sector: -39.30% Industry: -39.30%

EV/EBITDA

99.39

Sector: -4.10 Industry: -4.10

EV/EBIT

114.31

Sector: -4.18 Industry: -4.18

PRICE-TO-ASSETS

8.14

Sector: 1.47 Industry: 1.47

BVPS

7.78

Sector: 1.88 Industry: 1.88

EPS

4.18

Sector: -2.14 Industry: -2.14

EQUITY-TO-ASSETS RATIO

0.21

Sector: 0.42 Industry: 0.42

LIABILITIES / ASSETS

0.79

Sector: 0.40 Industry: 0.40

CAGR REVENUE 5 YEARS

38.40%

Sector: - Industry: -

CAGR PROFIT 5 YEARS

0.00%

Sector: - Industry: -

FAIR VALUE OF Alnylam Pharmaceuticals ACCORDING TO BENJAMIN GRAHAM

Graham's Fair Value

The Fair Value formula was created by Benjamin Graham to identify stocks with appreciation potential or that are being traded for less than they are worth. Graham was one of the greatest investors in history and Warren Buffett’s mentor.

Current Price

$ 295.63

Fair Value

$ 27.05

Upside Return potential.

-90.85%

See Graham's ranking

Because it considers equity value in its calculation, this formula may not work well for technology companies.

This is not a buy/sell recommendation; the fair value calculation takes into account only the formula created by Benjamin Graham, published in the book The Intelligent Investor.

Fundamentals ALNY

DRAG THE FRAME TO SEE MORE DATA

Stock Comparison Tool

DRAG THE FRAME TO SEE MORE DATA

	p/e	p/bv	ROE	dy	market cap	net margin
JNJ	25.65	6.65	25.92%	2.32%	$ 539.72 B	21.83%
PFE	19.57	1.62	8.29%	6.68%	$ 146.58 B	11.83%
ABBV	106.01	-58.28	-54.98%	3.10%	$ 385.36 B	5.79%
NVO	10.68	6.45	60.40%	4.09%	$ 202.51 B	37.15%
MRK	32.85	6.39	19.45%	2.80%	$ 293.48 B	13.59%
AZN	27.68	6.07	21.93%	1.72%	$ 287.60 B	17.19%
GILD	18.12	7.13	39.33%	2.37%	$ 166.96 B	30.99%
BMY	16.02	5.80	36.19%	4.37%	$ 116.53 B	15.01%
ZTS	12.27	10.03	81.75%	2.64%	$ 32.42 B	27.79%
REGN	14.45	2.03	14.08%	0.58%	$ 63.94 B	29.65%
HALO	22.51	35.75	158.82%	0.00%	$ 7.85 B	23.13%
AMGN	23.32	19.79	84.87%	2.87%	$ 181.87 B	20.96%
MCK	19.02	-108.61	-570.98%	0.43%	$ 90.58 B	1.18%
HRMY	12.58	2.01	16.00%	0.00%	$ 1.83 B	16.20%
VRTX	26.20	5.87	22.41%	0.00%	$ 113.68 B	35.51%
CAH	29.74	-17.31	-58.20%	1.04%	$ 46.25 B	0.62%
ADMA	11.39	4.82	42.37%	0.00%	$ 1.88 B	32.43%

Stock vs Indice Comparison Tool

If you had invested

years ago

2 years

5 years

10 years

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

ALNY Historical Dividends

current DY: 0.00%

5-year average DY: 0.00%

no dividend paid in the period.

ABOUT Alnylam Pharmaceuticals

Alnylam Pharmaceuticals Inc.

Average Investor10 user rating

4.0 (6 people)

United States

23 years

Founded: 2003

2004

Time since IPO - 22 years

1.453

Employees

Alnylam Pharmaceuticals Inc. (United States) is listed on the Nasdaq and has a market capitalization of $41.74 Billions, with shareholders equity totaling $1.08 Billion.

The company employs approximately 1.453 people and operates in the Health Care sector, within the Biotechnology industry.

Over the past 12 months, Alnylam Pharmaceuticals Inc. reported $4.29 Billions in revenue, generating net income of $577.22 Millions.

Key financial metrics include a P/E ratio of 72.32, a price-to-book (P/B) ratio of 38.82, and a trailing twelve-month dividend yield of 0.00%.

The company trades under the ticker ALNY.

Market cap

$ 41.74 Billions

Net worth

$ 1.08 Billion

$ 1,075,380,000.00

Assets

$ 5.13 Billions

$ 5,129,547,000.00

Total Shares Outstanding

138.23 Millions

138,226,000

Average Daily Trading Volume

$ 1.36 Million

$ 1,364,751.00

Sector

Health Care

Industry

Biotechnology

ALNY

revenue by Business Segment Alnylam Pharmaceuticals

Revenue by Region Alnylam Pharmaceuticals

ALNY revenue and profits

Financial Results ALNY

DRAG THE FRAME TO SEE MORE DATA

ALNY cash flow

DRAG THE FRAME TO SEE MORE DATA

Discover more stocks

BFRA - Biofrontera

$ - -0,00% (12M)

P/E

0.00

0.00%

ROE

-893.55%

P/BV

0.00

MCK - McKesson

$ 734.82 2,33% (12M)

P/E

19.02

0.43%

ROE

-570.98%

P/BV

-108.61

CAH - Cardinal Health

$ 195.15 27,47% (12M)

P/E

29.74

1.04%

ROE

-58.20%

P/BV

-17.31

JNJ - Johnson & Johnson

$ 223.51 48,70% (12M)

P/E

25.65

2.32%

ROE

25.92%

P/BV

6.65

MRK - Merck & Co.

$ 115.17 57,63% (12M)

P/E

32.85

2.80%

ROE

19.45%

P/BV

6.39

AZN - AstraZeneca

$ 179.71 27,31% (12M)

P/E

27.68

1.72%

ROE

21.93%

P/BV

6.07

ABBV - AbbVie

$ 212.93 17,49% (12M)

P/E

106.01

3.10%

ROE

-54.98%

P/BV

-58.28

NVO - Novo Nordisk

$ 44.07 --36,56% (12M)

P/E

10.68

4.09%

ROE

60.40%

P/BV

6.45

BFRA - Biofrontera

$ - -0,00% (12 M)

P/L

0.00

0.00%

ROE

-893.55%

P/VP

0.00

MCK - McKesson

$ 734.82 2,33% (12 M)

P/L

19.02

0.43%

ROE

-570.98%

P/VP

-108.61

CAH - Cardinal Health

$ 195.15 27,47% (12 M)

P/L

29.74

1.04%

ROE

-58.20%

P/VP

-17.31

JNJ - Johnson & Johnson

$ 223.51 48,70% (12 M)

P/L

25.65

2.32%

ROE

25.92%

P/VP

6.65

MRK - Merck & Co.

$ 115.17 57,63% (12 M)

P/L

32.85

2.80%

ROE

19.45%

P/VP

6.39

AZN - AstraZeneca

$ 179.71 27,31% (12 M)

P/L

27.68

1.72%

ROE

21.93%

P/VP

6.07

ABBV - AbbVie

$ 212.93 17,49% (12 M)

P/L

106.01

3.10%

ROE

-54.98%

P/VP

-58.28

NVO - Novo Nordisk

$ 44.07 --36,56% (12 M)

P/L

10.68

4.09%

ROE

60.40%

P/VP

6.45

Frequently Asked Questions

What is the price of Alnylam Pharmaceuticals (ALNY) today?

The current price of Alnylam Pharmaceuticals (ALNY) is $ 295.63, representing a -2.93% gain over the past year. The stock began the year trading around $ 397.65 and is currently priced at $ 295.63. You can follow the real-time price chart, review historical performance, and track broader market trends directly on the platform.

When does Alnylam Pharmaceuticals (ALNY) pay dividends?

Alnylam Pharmaceuticals (ALNY) did not pay dividends over the past year.

Is Alnylam Pharmaceuticals (ALNY) a good investment?

Alnylam Pharmaceuticals (ALNY) is currently trading at $ 295.63 with a P/E ratio of 72.32. This represents a -5,248% premium compared to its historical average P/E. Over the past year, the stock has gained -2.93 and paid $ 0.00 in dividends, resulting in a dividend yield of 0.00%. The total shareholder return over the same period was -2.93%.

Investors should keep in mind that past performance does not guarantee future results. This information is provided for educational purposes only and should not be considered investment advice.

How can I buy Alnylam Pharmaceuticals (ALNY) stock?

You can buy Alnylam Pharmaceuticals (ALNY) shares through any brokerage account that provides access to U.S. stock exchanges. After opening and funding your account, simply search for the ticker symbol ALNY and place a buy order. Before investing, consider factors such as your financial goals, risk tolerance, and overall portfolio allocation.

How much would 100 shares of Alnylam Pharmaceuticals (ALNY) yield today?

Over the past month, Alnylam Pharmaceuticals (ALNY) has returned -0.16% — -2.93% over the past year, and 100.71% over the past five years, including price appreciation and dividends.

In the last 12 months, the company paid a total of 0.00 per share in dividends, resulting in a dividend yield of 0.00%.

If you were to purchase 100 shares of Alnylam Pharmaceuticals (ALNY) today at the current price of $ 295.63 your total investment would be $ 29,563.00.

Based on historical performance, the investment would have grown to approximately:

$ 28,696.80 after 1 year
$ 59,335.90 after 5 years
$ 120,380.54 after 10 years

Past performance does not guarantee future results. This content is for informational purposes only and should not be considered investment advice.

ALNY

Alnylam Pharmaceuticals Inc.

Price

return (12m)

p/e

p/bv

DIVIDEND YIELD

Return on Investment ALNY

review the fundamentals of Alnylam Pharmaceuticals shares

P/E

P/S (PSR)

P/BV

DIVIDEND YIELD (DY)

ROA

ROE

ROIC

NET MARGIN

GROSS MARGIN

OPERATING MARGIN

EV/EBITDA

EV/EBIT

PRICE-TO-ASSETS

BVPS

EPS

EQUITY-TO-ASSETS RATIO

LIABILITIES / ASSETS

CAGR REVENUE 5 YEARS

CAGR PROFIT 5 YEARS

Graham's Fair Value

current DY: 0.00%

5-year average DY: 0.00%

ABOUT Alnylam Pharmaceuticals

Alnylam Pharmaceuticals Inc.

United States

23 years

2004

1.453

PROFIT X PRICE ALNY

Financial Results ALNY

ALNY cash flow

Asset, Revenue and Profit Growth - ALNY

ALNY balance sheet

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

JNJ - Johnson & Johnson

MRK - Merck & Co.

AZN - AstraZeneca

ABBV - AbbVie

NVO - Novo Nordisk

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

JNJ - Johnson & Johnson

MRK - Merck & Co.

AZN - AstraZeneca

ABBV - AbbVie

NVO - Novo Nordisk

Frequently Asked Questions